Abstract 606P
Background
Cutaneous melanoma is considered a rare but lethal cancer among Asians. Prognosis is generally worse with high rates of recurrences and mortality. Clinical presentations show striking differences with cutaneous melanoma among Caucasian. Acral lentiginous and nodular melanoma are the most common subtypes among Asian. Patterns of mutations and molecular alterations and the association with prognosis are not yet known among melanoma patients in Indonesia. This study aims to analyze association between BRAF dan NRAS mutations with overall survival of melanoma patients in Indonesia.
Methods
DNA from formalin-fixed paraffin embedded tissues from melanoma patients were extracted. PCR and pyrosequencing were performed to detect mutations in the BRAF dan NRAS genes.
Results
Of 51 melanoma patients, 44 patients (86.3%) were diagnosed with Breslow thickness more than 4 mm (T4). In the primary cutaneous melanoma lesions, 33 (67%) patients had ulceration, 47 patients (92.2%) had diameter more than 6 mm, and 30 patient (58.2%) had positive regional lymph nodes. In this study, BRAF mutations were found in 26 patients (56%) and NRAS mutations were found in 5 patients (9.8%). BRAF mutations were found in older age than 65 years although the difference was not significant (OR 2.205, 95%CI: 0.558-8.717, P=0.259). BRAF mutations were associated with significantly lower overall survivals compared to wild-type (median survivals were 18 vs 34 months, P=0.042). Although patients with NRAS mutations had shorter survival, the difference was not statistically significant (P=0.120). Patients with BRAF or NRAS were associated with significant lower overall survivals compared to those with wild-type (Median survivals were 19 vs 35 months, P=0.044).
Conclusions
BRAF and / or NRAS mutations were associated with shorter survival among cutaneous melanomas in Indonesia with predominant subtypes of acral lentiginous and nodular melanomas. Larger study from Asian population is required to extend our finding to establish a prognostic marker as well as a potential targeted treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gadjah Mada University.
Funding
Gadjah Mada University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract